MARCOS
GONZÁLEZ DÍAZ
Ikertzailea 1993-2023 tartean
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosUniversity of Texas MD Anderson Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (4)
2014
-
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477
2010
-
International network of cancer genome projects
Nature, Vol. 464, Núm. 7291, pp. 993-998
2009
-
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide
Leukemia and Lymphoma, Vol. 50, Núm. 8, pp. 1283-1289